Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.54 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.54 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.54 |
| ▸ | TBK1 | Q9UHD2 | 13/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17120694 | 0.89 | KDM4E (0.61) | RPS6KA3RPS6KA2RPS6KA1TBK1KDM4E | |
| SCHEMBL17120693 | 0.87 | CNR2 (0.46) | RPS6KA3RPS6KA2RPS6KA1TBK1 | |
| SCHEMBL17120696 | 0.85 | RPS6KA3 (0.55) | RPS6KA3RPS6KA2RPS6KA1TBK1 | |
| SCHEMBL17120707 | 0.80 | MAPT (0.54) | TBK1KDM4ELMNANSD2MAPT | |
| SCHEMBL19095257 | 0.79 | ROCK2 (0.58) | TBK1KDM4ELMNANSD2MAPT | |
| SCHEMBL17120730 | 0.77 | LMNA (0.50) | KDM4ELMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL2984516 | 0.76 | HRH3 (0.64) | RPS6KA3RPS6KA1LMNAALDH1A1 | |
| SCHEMBL29662934 | 0.76 | KDM4E (0.44) | TBK1KDM4ELMNANSD2MAPT | |
| SCHEMBL17099818 | 0.76 | KDM4E (0.44) | TBK1KDM4ELMNANSD2MAPT | |
| SCHEMBL19095141 | 0.75 | ROCK2 (0.53) | TBK1KDM4ELMNANSD2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3119761-B1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210371390-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2021-12-02 | — | — | US | disclosed |
| US-20210369873-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY | Amydis, Inc. | 2021-12-02 | — | — | US | disclosed |
| US-10934264-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200123118-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-04-23 | — | — | US | disclosed |
| US-10370345-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-06 | — | — | US | disclosed |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170248616-A1 | IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT | Amydis, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2016-11-10 | — | — | US | disclosed |
| WO-2015143185-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | RPS6KA3 3699/4885RPS6KA2 3404/4885RPS6KA1 3629/4885 |
| US-20200123118-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | RPS6KA3 3699/4885RPS6KA2 3404/4885RPS6KA1 3629/4885 |
| US-20210369873-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY | S100B, FABP7, CRYAB | RPS6KA3 2288/4885RPS6KA2 2733/4885RPS6KA1 2586/4885 |
| US-20210371390-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | RPS6KA3 3699/4885RPS6KA2 3404/4885RPS6KA1 3629/4885 |
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | RPS6KA3 3699/4885RPS6KA2 3404/4885RPS6KA1 3629/4885 |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, APBA1, CRYAA | RPS6KA3 3585/4885RPS6KA2 3266/4885RPS6KA1 3519/4885 |
| US-10370345-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | RPS6KA3 3699/4885RPS6KA2 3404/4885RPS6KA1 3629/4885 |
| US-10934264-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | RPS6KA3 3699/4885RPS6KA2 3404/4885RPS6KA1 3629/4885 |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | APP, APBA1, CRYAA | RPS6KA3 3585/4885RPS6KA2 3266/4885RPS6KA1 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.